Close menu




December 8th, 2022 | 09:09 CET

Shares: Buy FlatexDegiro now? Uniper gambles, Aspermont before multiplication and Nel ASA?

  • Fintech
  • Investments
Photo credits: pixabay.com

FlatexDegiro's revenue and profit warning has shocked shareholders. In just three trading days, it went down by about 40%. Is it now worthwhile to enter again? Analysts have a clear opinion. Can the Uniper share price halve? Analysts believe this is possible. In addition, the upcoming Extraordinary General Meeting promises to be exciting. In contrast, the media company and fintech Aspermont is doing well operationally. Therefore, analysts believe that a price multiplication is possible. The share prices of Nel and Plug Power are currently weak. Analysts are confident but currently surprisingly quiet.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: FLATEX AG NA O.N. | DE000FTG1111 , UNIPER SE NA O.N. | DE000UNSE018 , ASPERMONT LTD | AU000000ASP3 , NEL ASA NK-_20 | NO0010081235

Table of contents:


    Aspermont: Multiplication potential

    Analysts at GBC Research continue to believe that Aspermont's stock has the potential to multiply. Aspermont provides over 4 million customers from the global commodities industry with information and an increasing number of financial services - cloud-based. That makes the Australians a media and fintech company rolled into one. In its latest report following the release of preliminary figures, GBC is pleased with the Company's operational performance. With revenue growth of 17% to AUD 18.7 million in fiscal 2022 (ending September 30), Aspermont had finally put the constraints of the COVID-19 pandemic behind it. Particularly encouraging: the recurring revenue share increased from 70% to 75%. In fiscal 2023, which is now underway, growth could even increase to 20%, analysts said.

    Things are also looking good on the earnings side. Aspermont's EBITDA from operations increased by 40% to AUD 2.3 million in fiscal 2022. In addition, the Australians have cash on hand of AUD 6.6 million, and one is increasingly able to finance growth investments from cash reserves and cash flow. The Company itself is also confident. Alex Kent, Managing Director of Aspermont, said, "As per prior guidance, FY22 was an excellent year for Aspermont, at all levels. Given the challenging global conditions, our consistent growth confirms the resilience of our business models and key management to deliver progress regardless of overall financial conditions."

    Aspermont has announced further sustainable growth. In addition, the market in North America is to be explored soon. In line with this, a listing on the US stock exchange Nasdaq is likely.

    At AUD 0.02, the market capitalization is AUD 31.4 million. Anything but a lot for a company increasingly growing in the high-margin cloud business. GBC also sees it this way and recommends the share as a buy with a price target of AUD 0.11. (Study for download more-ir.de/d/26135.pdf)

    Uniper: Only for gamblers?

    Uniper is deep in the crisis. Likely no other German company has been so severely affected by Russia's war of aggression on Ukraine. Gas replacement costs now add up to EUR 11.6 billion. The future of the Company is uncertain. Shortly before Christmas, shareholders are expected to approve the stabilization package agreed upon with the German government at an extraordinary shareholders' meeting. The government is to pay EUR 1.70 per Uniper share and subsequently hold 99% of the shares. Nevertheless, the stock is currently trading at EUR 3.40 and has become the plaything of gamblers.

    Analysts also believe that the share price is too high. Most recently, UBS renewed its Sell recommendation and reduced the price target from EUR 2 to EUR 1.80. The analysts see "no solid fundamental basis for a more optimistic assessment". The analysts attribute the interim doubling of the share price to over EUR 6 to the closing of short sales. Uniper itself is seeking damages from Gazprom. Thus, arbitration proceedings against Gazprom Export before an international arbitration court have been applied for. Whether this should one day be successful is anything but certain.

    FlatexDegiro: Buy after price slide?

    FlatexDegiro made headlines and a crashing share price this week. The reasons were sales and profit warnings from the online broker and investigations by BaFin. Yesterday, the share fell again by 5%. Thus, the security has lost about 40% in three trading days and is now trading at just over EUR 6. Analysts consider this to be too little. Jefferies initially confirmed its Buy recommendation but reduced its price target from EUR 18 to EUR 13. Yesterday, Goldman Sachs changed its stance and downgraded the share from "Buy" to "Neutral". The analysts more than halved the price target from EUR 19 to EUR 8. The BaFin investigations show that the regulatory environment is becoming more difficult. From the analysts' point of view, there are also operational problems: Growth is slowing down, and costs are rising. This trend is likely to continue in 2023.

    Nel and Plug Power: Analysts on the sidelines

    While the shares of Nel and Plug Power lost again significantly yesterday, analysts are surprisingly calm about the two hydrogen pure plays at the moment. It seems they want to wait for the results of the current quarter. With Plug Power, there is no sell recommendation at present, according to wsj.com. Most recently, Citigroup reduced the price target for the Plug Power share from USD 28 to USD 20. The recommendation is still Buy. The stock is currently trading between USD 13 and 14. The last assessment for Nel was made some time ago. Most recently, Jefferies confirmed the buy recommendation for the hydrogen hopeful from Norway. The price target is NOK 19. Currently, the share is trading at around NOK 14.50.


    Aspermont is strong in growth, debt-free and appears favorably valued. The high proportion of recurring revenues is reassuring, and a possible Nasdaq listing brings fantasy. Nel and Plug Power continue to receive buy recommendations from analysts, but there is no urgent need for short-term investors to buy them. Valuations remain high, and both companies need to resume faster growth and get their costs under control. FlatexDegiro has deeply disappointed investors for now. But at least for analysts, the price slide proved too steep. Uniper is and remains only something for gamblers.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read